SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest
event reported):
December 17,
2008
PHARMA-BIO SERV,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
|
0-50956
|
20-0653570
|
(State or other
jurisdiction
|
(Commission
|
(IRS
Employer
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
Pharma-Bio Serv
Building
Industrial Zone Lot 14,
Barrio Higuillar, Dorado,
Puerto Rico
|
00646
|
(Address of principal executive
offices)
|
(Zip
Code)
|
Registrant’s telephone number,
including area code:
(787)
278-2709
NONE
(Former name or former address, if
changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the Registrant under any of the following
provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
On December
17, 2008, Pharma-Bio Serv, Inc. (the "Company") amended the Employment Agreement
of Pedro Lasanta, the Company's Chief Financial Officer, dated
November 5, 2007. The amendment provides for an indefinite term of the
contract, an increase in base salary to $110,000 per year and an annual bonus in
cash or Company stock options to be granted based on performance metrics to be
established. Pursuant to the Agreement, Mr. Lasanta will be granted
options to purchase 30,000 shares of Company common stock having an exercise
price equal to fair market value on the date of grant and vesting
three equal annual installments beginning one year from November 1,
2008. In addition, upon termination of Mr. Lasanta's employment for reasons
other than those set forth in his Employment Agreement, Mr. Lasanta shall
receive a lump-sum severance payment in an amount equivalent to six months of
his salary at the time of the termination, less legal withholdings, or the
severance established by PR labor law No. 80 of May 30, 1976, known as the
“Wrongful Discharge Act” (“Ley de Despido Injustificado”), whichever amount is
higher. All other terms and conditions of Mr. Lasanta's employment
agreement remain the same.
A copy
of the Amendment is attached as Exhibit 10.1 to this report and is incorporated
herein by this reference.
Item 9.01
Financial Statements and
Exhibits.
10.1
|
Amendment
dated December 17, 2008 to Employment Agreement dated November
5, 2007, between Pedro Lasanta and the
Company.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
PHARMA-BIO
SERV, INC.
|
|
|
|
Date: December 23,
2008
|
By:
|
/s/ Elizabeth
Plaza
|
|
Elizabeth Plaza, Chief Executive
Officer
|
EXHIBIT
INDEX
10.1
|
Amendment
dated December 17, 2008 to Employment Agreement dated November
5, 2007, between Pedro Lasanta and the
Company.
|
AMENDMENT
TO EMPLOYMENT AGREEMENT
Amendment
to Employment Agreement dated November 5, 2007 between Pharma-Bio Serv, Inc.,
hereinafter ("Company") and Pedro J. Lasanta ("Executive").
WHEREAS,
Company and Executive wish to continue Executive's employment with the
Company; and
WHEREAS,
in consideration for Executive's continued employment, the parties wish to
modify certain provisions of the Employment Agreement,
NOW
THEREFORE, the parties hereby agree as follows:
|
1.
|
That
pursuant to paragraph 1(b) of that certain Employment Agreement dated
November 5, 2007, is hereby modified and amended so as to extend the
“Term” for an “Indefinite amount of time” (“Employment Term” or
“Term”).
|
|
2.
|
That Executive's
compensation pursuant to paragraph 3(a) of that certain Employment
Agreement dated November 5, 2007, is hereby modified and amended so as to
increase Executi
ve's annual salary,
as of November 1, 2008,
from $100,000 to
$110,000 per annum.
Salary shall be paid in such
installments as the Company regularly pays its executive officers, but not
less frequently than semi-monthly. Executive’s salary will be
revised annually based upon performance evaluation following Company’s
performance review process and subject to the financial situation of the
Company.”
|
|
3.
|
That
pursuant to paragraph 3 of that certain Employment Agreement dated
November 5, 2007, is hereby modified and amended so it reads as
follows:
|
“3.
(vii) Annual bonus, either in cash or in the form of stock options,
shall be granted to the Executive based on performance metrics established and
agreed upon by the Company’s senior management. Benefit is based on a
successful achievement of Executive’s performance goals and the recommendation
of the CEO. For this purpose, performance appraisal will take place once a
year.”
|
4.
|
That
pursuant to paragraph 3 of that certain Employment Agreement dated
November 5, 2007, is hereby modified and amended so as to add clause
3.(viii) as follows:
|
“3.
(viii)
F
or his services
during the Employment Term, the Company shall issue to Executive incentive stock
options (“Stock Options”) to purchase 30,000 shares of PBSV common stock, at
fair market value on the date of grant, as determined by PBSV’s Compensation
Committee, pursuant to PBSV’s 2005 Long-Term Incentive
Plan. However, such stock options shall vest in accordance to
the following schedule: 33.3% as of the end of one (1) year after the
Grant Date; 66.7% as of the end of two (2) years after the Grant Date; and 100%
as of the end of three (3) years after the Grant Date. For the
purpose of the vesting schedule only, Grant Date shall be November 1
st
,
2008. In the event that the Company terminates this Agreement and
Executive’s employment other than for reasons set forth in Sections 5(a), 5(b)
or 5(c) of this Agreement, including termination due to an acquisition, all
unvested Stock Options will be considered to be immediately exercisable and
vested.”
|
5.
|
That
pursuant to paragraph 5.(e) and 5.(e)(i) of that certain Employment
Agreement dated November 5, 2007, is hereby modified and amended so as to
read as follows:
|
“5.
(e) In the event that the Company terminates this Agreement and
Executive’s employment other than for reasons set forth in Sections 5(a), 5(b)
or 5(c), including termination due to an acquisition:
(i) The
Company shall pay to Executive within 30 days after the date of his termination
a lump-sum severance payment in an amount equivalent to six months of his salary
at the time of the termination, less legal withholdings, or the severance
established by PR labor law No. 80 of May 30, 1976, known as the “Wrongful
Discharge Act” (“Ley de Despido Injustificado”), whichever amount is
higher. Also, the company shall pay to the Executive any bonuses that
the Executive may have earned up to the date of his termination, and any unused
accrued vacation days.”
In
all other respects the Employment Agreement dated November 5, 2007,
shall remain in full force and effect and unaltered.
IN WITNESS WHEREOF
, the
parties have executed this Agreement in Dorado, Puerto Rico, this 17th day of
December, 2008.
PHARMA-BIO
SERV, INC.
By:
/s/ Elizabeth
Plaza
Name:
Elizabeth Plaza
Title: President
& CEO
EXECUTIVE:
/s/ Pedro J.
Lasanta
Pedro J. Lasanta, CFO